Energy metabolism in H460 lung cancer cells: Effects of histone deacetylase inhibitors

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Amoêdo, Nívea Dias ^a   Rodrigues, Mariana Figueiredo ^a   Pezzuto, Paula ^a   Galina, Antonio ^a   da Costa, Rodrigo Madeiro ^a   de Almeida, Fábio Ceneviva Lacerda ^a   El Bacha, Tatiana ^a   David Rumjanek, Franklin ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BUTYRIC ACID; CITRATE SYNTHASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLUTAMINE; HEXOKINASE; HEXOKINASE 1; HEXOKINASE 2; HISTONE DEACETYLASE INHIBITOR; LACTATE DEHYDROGENASE; MESSENGER RNA; MITOCHONDRIAL DNA; MITOFUSIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE; PYRUVATE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL; BUTYRIC ACID DERIVATIVE; GLUCOSE DEHYDROGENASE; HYDROXAMIC ACID; LACTIC ACID DERIVATIVE; SLC2A1 PROTEIN, HUMAN; SLC2A3 PROTEIN, HUMAN; SUCCINATE DEHYDROGENASE;

AEROBIC METABOLISM; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENERGY METABOLISM; ENZYME KINETICS; ENZYME RELEASE; GENE EXPRESSION; GLUCOSE TRANSPORT; H460 CELL; HUMAN; HUMAN CELL; LUNG CANCER; METABOLOMICS; MITOCHONDRIAL RESPIRATION; MITOSIS INHIBITION; OXYGEN CONCENTRATION; OXYGEN CONSUMPTION; PENTOSE PHOSPHATE CYCLE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL RESPIRATION; CELL SHAPE; DRUG EFFECT; ENZYMOLOGY; GLYCOLYSIS; LUNG TUMOR; METABOLISM; MITOCHONDRION; PATHOLOGY; PROTEIN BINDING; TUMOR CELL LINE;

BUTYRATES; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL RESPIRATION; CELL SHAPE; ENERGY METABOLISM; GLUCOSE 1-DEHYDROGENASE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; GLYCOLYSIS; HEXOKINASE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; L-LACTATE DEHYDROGENASE; LACTATES; LUNG NEOPLASMS; MITOCHONDRIA; PROTEIN BINDING; PYRUVATE KINASE; SUCCINATE DEHYDROGENASE;

EID: 79960574987     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022264     Document Type: Article

References (40)

1. Warburg O, (1956) On respiratory impairment in cancer cells. Science 124: 269-270.
2. Crabtree HG, (1929) Observations on the carbohydrate metabolism of tumours. Biochem J 23: 536-545.
3. Annibaldi A, Widmann C, (2010) Glucose metabolism in cancer cells. Curr Opin Clin Nutr Metab Care 13: 466-470.
4. Vander Heiden MG, Cantley LC, Thompson CB, (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
5. Semenza GL, (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51-56.
6. Abu-Hamad S, Arbel N, Calo D, Arzoine L, Israelson A, et al. (2009) The VDAC1 N-terminus is essential both for apoptosis and the protective effect of anti-apoptotic proteins. J Cell Sci 122: 1906-1916.
7. Lee MN, Lee SN, Kim SH, Kim B, Jung BK, et al. (2010) Roles of arrest-defective protein 1(225) and hypoxia-inducible factor 1alpha in tumor growth and metastasis. J Natl Cancer Inst 102: 426-442.
8. Yang XJ, Seto E, (2007) HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26: 5310-5318.
9. Ponchaut S, van Hoof F, Veitch K, (1992) Cytochrome aa3 depletion is the cause of the deficient mitochondrial respiration induced by chronic valproate administration. Biochem Pharmacol 43: 644-647.
10. Silva MF, Ruiter JP, L IJ, Jakobs C, Duran M, et al. (2001) Differential effect of valproate and its Delta2- and Delta4-unsaturated metabolites, on the beta-oxidation rate of long-chain and medium-chain fatty acids. Chem Biol Interact 137: 203-212.
11. Turnbull DM, Bone AJ, Bartlett K, Koundakjian PP, Sherratt HS, (1983) The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats. Biochem Pharmacol 32: 1887-1892.
12. Alcarraz-Vizan G, Boren J, Lee WN, Cascante M, (2010) Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation. Metabolomics 6: 229-237.
13. Boren J, Lee WN, Bassilian S, Centelles JJ, Lim S, et al. (2003) The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation. J Biol Chem 278: 28395-28402.
14. Wardell SE, Ilkayeva OR, Wieman HL, Frigo DE, Rathmell JC, et al. (2009) Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol 23: 388-401.
15. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
16. Hamilton SD, Pardue HL, (1984) Quantitation of lactate by a kinetic method with an extended range of linearity and low dependence on experimental variables. Clin Chem 30: 226-229.
17. Hutter E, Renner K, Pfister G, Stockl P, Jansen-Durr P, et al. (2004) Senescence-associated changes in respiration and oxidative phosphorylation in primary human fibroblasts. Biochem J 380: 919-928.
18. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
19. Pereira da Silva AP, El-Bacha T, Kyaw N, dos Santos RS, da-Silva WS, et al. (2009) Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 417: 717-726.
20. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E, (2007) Energy metabolism in tumor cells. FEBS J 274: 1393-1418.
21. Gatenby RA, Gillies RJ, (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899.
22. Boren J, Montoya AR, de Atauri P, Comin-Anduix B, Cortes A, et al. (2002) Metabolic control analysis aimed at the ribose synthesis pathways of tumor cells: a new strategy for antitumor drug development. Mol Biol Rep 29: 7-12.
23. Cervera AM, Apostolova N, Crespo FL, Mata M, McCreath KJ, (2008) Cells silenced for SDHB expression display characteristic features of the tumor phenotype. Cancer Res 68: 4058-4067.
24. King A, Selak MA, Gottlieb E, (2006) Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 25: 4675-4682.
25. da-Silva WS, Gomez-Puyou A, de Gomez-Puyou MT, Moreno-Sanchez R, De Felice FG, et al. (2004) Mitochondrial bound hexokinase activity as a preventive antioxidant defense: steady-state ADP formation as a regulatory mechanism of membrane potential and reactive oxygen species generation in mitochondria. J Biol Chem 279: 39846-39855.
26. Meyer LE, Machado LB, Santiago AP, da-Silva WS, De Felice FG, et al. (2006) Mitochondrial creatine kinase activity prevents reactive oxygen species generation: antioxidant role of mitochondrial kinase-dependent ADP re-cycling activity. J Biol Chem 281: 37361-37371.
27. Merkwirth C, Langer T, (2008) Mitofusin 2 builds a bridge between ER and mitochondria. Cell 135: 1165-1167.
28. Feron O, (2009) Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 92: 329-333.
29. Guan KL, Xiong Y, (2010) Regulation of intermediary metabolism by protein acetylation. Trends Biochem Sci.
30. Ganapathy V, Thangaraju M, Prasad PD, (2009) Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121: 29-40.
31. Lecona E, Olmo N, Turnay J, Santiago-Gomez A, Lopez de Silanes I, et al. (2008) Kinetic analysis of butyrate transport in human colon adenocarcinoma cells reveals two different carrier-mediated mechanisms. Biochem J 409: 311-320.
32. Leschelle X, Delpal S, Goubern M, Blottiere HM, Blachier F, (2000) Butyrate metabolism upstream and downstream acetyl-CoA synthesis and growth control of human colon carcinoma cells. Eur J Biochem 267: 6435-6442.
33. Sanderson L, Taylor GW, Aboagye EO, Alao JP, Latigo JR, et al. (2004) Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice. Drug Metab Dispos 32: 1132-1138.
34. Kroemer G, Pouyssegur J, (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482.
35. Gould GW, Holman GD, (1993) The glucose transporter family: structure, function and tissue-specific expression. Biochem J 295 (Pt 2): 329-341.
36. Marin-Hernandez A, Gallardo-Perez JC, Rodriguez-Enriquez S, Encalada R, Moreno-Sanchez R, et al. (2011) Modeling cancer glycolysis. Biochim Biophys Acta 1807: 755-767.
37. Detmer SA, Chan DC, (2007) Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol 8: 870-879.
38. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R, (2009) HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 9: 1084-1101.
39. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, et al. (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 107: 8788-8793.
40. Lamprecht W, Trautschold I, (1974) ATP determination with hexokinase and glucose-6-phosphate dehydrogenase. In: Bergmeyer HV, editors. Methods of Enzymatic Analysis 2nd ed pp. 2101-2110.